Skip to main content
LGND logo

Ligand Pharmaceuticals Incorporated (LGND) Stock: Price, Forecast & Analyst Target

Ligand Pharmaceuticals Incorporated (LGND) — MoonshotScore 71/100 (Strong band), calculated Nov 18, 2026. Price $286.85 (-0.03%), as of the Nov 20, 2026 trading session; market cap $5.74B. Expected results Feb 25, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$286.85 −$0.09 (-0.03%) Market Cap $5.74B

Ligand Pharmaceuticals Incorporated · LGND · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: Ligand supplies both commercialized drugs across cancer, infectious disease, and bone health, and collects royalties from partner programs—a mix of direct sales and passive income flows. Whether the royalty foundation will cushion earnings through product cycles or whether the company must continually expand its own portfolio determines whether this business compounds or merely treads water.

Price as of Nov 20, 2026

Key Statistics

71 of 100

MoonshotScore v2 · Ligand Pharmaceuticals (LGND)

Strong
Business Quality Elite (83)
Financial Safety Strained (20)
Valuation Rich (33)
Growth Durability Compounding (94)
Momentum Surging (89)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and elite growth, but a fragile balance sheet and an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Strained; Valuation: Rich; Growth Durability: Compounding; Momentum: Surging.

Enterprise value relative to EBITDA is the main valuation drag relative to sector peers.

  • quarterly revenue $115M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z 3.36 · Piotroski F 5

Holding back: balance-sheet strain, a rich price

Helping: business quality, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for LGND (58 recorded, newest six shown)
RecordedScoreBand
75Strong
74Strong
74Strong
71Strong
71Strong
71Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$286.85
Change on the day-0.03%
52-week range$175.89–$326.63
Market capitalisation$5.74B—
Price / earnings (trailing)113.44
Shares traded on the day259.8K
Beta (volatility vs the S&P 500)1.03

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $182, high $323, latest $287. 4 reported quarters marked, 3 above and 1 below the recorded estimate. $323 $182 high $323 Feb 26, 2026 · Earnings results · reported above the recorded estimate · close $1981May 14, 2026 · Earnings results · reported below the recorded estimate · close $2132Aug 6, 2026 · Earnings results · reported above the recorded estimate · close $2933Oct 29, 2026 · Earnings results · reported above the recorded estimate · close $3234 Oct 17, 2025 Nov 20, 2026 · $287 $182Oct 17, 2025$191Oct 31, 2025$201Nov 14, 2025$203Nov 28, 2025$190Dec 12, 2025$196Dec 26, 2025$207Jan 9, 2026$201Jan 23, 2026$190Feb 6, 2026$184Feb 20, 2026$202Mar 6, 2026$205Mar 20, 2026$200Apr 2, 2026$232Apr 17, 2026$227May 1, 2026$213May 15, 2026$232May 29, 2026$256Jun 12, 2026$304Jun 26, 2026$316Jul 10, 2026$301Jul 24, 2026$293Aug 7, 2026$286Aug 21, 2026$286Sep 4, 2026$283Sep 18, 2026$303Oct 2, 2026$296Oct 16, 2026$323Oct 30, 2026$309Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Ligand Pharmaceuticals (LGND): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Weak
Valuation Weak
Growth Durability Strong
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Nov 21, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Strong
Debt/Equity Negative
ROE Neutral
Gross Margin Strong

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Ligand Pharmaceuticals (LGND), and what does it report?

Short answer · as of

Ligand maintains two revenue streams: direct sales from its own marketed drugs and royalties on partner-developed therapeutics.

This dual model produces exceptionally high gross margins because royalties require minimal fulfillment cost.

The financial statements separate royalty income from product sales, contract revenue, and Captisol material sales. Operating leverage emerges from the fact that royalty income grows with partner drug adoption while requiring little incremental spending.

2 · Latest results

What do the latest results show for Ligand Pharmaceuticals (LGND)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $115M.

The most recent quarter showed strong profitability and higher revenue than the prior quarter, with earnings per share materially positive. This reversal followed a period of losses and suggests demand has strengthened.

Management projects the just-closed acquisition will contribute meaningfully to earnings in coming periods, with the acceleration weighted toward later periods. The magnitude of the contribution is substantial enough to move company-wide earnings power.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$78.75M Oct 29, 2026
Latest report · revenue estimate
$77.00M Oct 29, 2026
Latest report · revenue vs estimate
Above estimate Oct 29, 2026
Latest report · EPS vs estimate
Above estimate Oct 29, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 29, 2026$78.75M$77.00M$2.6700$2.3300
Aug 6, 2026$63.69M$61.30M$2.3700$2.0100
May 14, 2026$51.72M$59.10M$1.6300$1.8400
Feb 26, 2026$59.67M$55.59M$2.0200$1.4600
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$115M$117M$5.68 (diluted)
Q4 FY2025$60M$45M$2.12 (diluted)
Q1 FY2026$52M-$13M-$0.67 (diluted)
Q2 FY2026$64M$49M$2.22 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Ligand Pharmaceuticals (LGND)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

The company holds cash substantially exceeding its debt, with liquidity ratios that indicate minimal near-term financing pressure. Quarterly operating results have been strong lately, translating to robust cash generation.

The risk lies in revenue concentration—a slowdown in major royalty-generating drugs would hollow out earnings—and in execution risk of bringing new programs to market if royalty partners falter. The company's small headcount also means that key personnel departures could disrupt operations.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 113.44 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
4 · What to check next?

What should you watch next at Ligand Pharmaceuticals (LGND)?

Short answer · as of

The next earnings report is expected on Feb 25, 2027.

Watch whether the recent acquisition delivers the projected earnings accretion and whether management's confidence in back-half contribution timing holds up. Equally important: track adoption trends for the major royalty-generating drug franchise.

Monitor whether the company returns to repurchasing shares, a signal that management believes the valuation is attractive relative to intrinsic value. Any material new clinical readouts from development programs warrant close attention.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The newest quarter held here (Q3 FY2025) was filed Nov 7, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Ligand Pharmaceuticals compare with its peers?

Short answer

Ligand Pharmaceuticals's score ranks 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Ligand differs from traditional pharmaceutical companies by deriving substantial income from royalty arrangements, which provides earnings stability during slow periods for its own portfolio. Unlike pure-royalty vehicles, it maintains its own marketed drugs with direct pricing power.

The lean headcount for a company of its revenue scale suggests a highly efficient model with outsourced development and commercial execution, which reduces fixed costs but increases dependence on partner execution and regulatory approval timelines.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$93.89 Nov 20, 2026$7.38B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$308.89 Nov 20, 2026$9.15B96 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$63.62 Nov 20, 2026$6.96B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$63.34 Nov 20, 2026$9.57B90 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$121.40 Nov 20, 2026$7.92B88 5-pillar Nov 18, 2026
Edgewise Therapeutics, Inc. (EWTX) Same industry, near in market value$39.91 Nov 20, 2026$4.37B84 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$17.58 Nov 20, 2026$5.04B83 5-pillar Nov 18, 2026
Enliven Therapeutics, Inc. (ELVN) Same industry, near in market value$46.53 Nov 20, 2026$3.42B72 5-pillar Nov 18, 2026
Ligand Pharmaceuticals (LGND) — this page$286.85$5.74B71
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$95.81 Nov 20, 2026$6.50B67 5-pillar Nov 18, 2026
Erasca, Inc. (ERAS) Same industry, near in market value$13.61 Nov 20, 2026$4.78B67 5-pillar Nov 18, 2026
Veradermics, Incorporated (MANE) Same industry, near in market value$119.52 Nov 20, 2026$5.04B66 5-pillar Nov 18, 2026
Belite Bio, Inc. (BLTE) Named competitor$127.38 Nov 20, 2026$5.17B64 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$326.00 – $406.00
Consensus target
$350.00
Median target
$345.00

Consensus record · Captured .

Measured against a quoted price of $286.85 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 10, 2026

Transactions
125
Identified insiders
10
Purchases
0
Sales
74
Other transactions
51

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held LGND in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported LGND in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Ligand Pharmaceuticals (LGND)?

Read these with our analysis →

Ligand Pharmaceuticals Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

What is Captisol and why does Ligand sell it?

Captisol is a proprietary solubilization technology that Ligand developed and now supplies to pharmaceutical manufacturers. Many of Ligand's own drugs use Captisol, but competitors also license and purchase it, creating a recurring material revenue stream. This segment diversifies revenue away from pure drug sales and provides high-margin, relatively non-volatile income.

Does Kyprolis generate most of Ligand's royalty income?

Kyprolis is a major contributor to royalty income, as a marketed cancer drug with established market share. However, the company also collects royalties from other partner drugs across its portfolio, spreading concentration risk. A sustained decline in Kyprolis adoption would meaningfully compress earnings, but would not eliminate the royalty base entirely.

Why did earnings swing so dramatically between quarters?

Pharmaceutical and royalty revenue can be lumpy, driven by partner sales, milestone achievements, and one-time adjustments. The swing from a material loss in the prior quarter to strong profitability reflects both cyclical partner performance and possibly upfront payments or milestone revenues. The company's business model amplifies these swings because operating leverage is high—a small change in royalty collections or partner sales drives large percentage changes in net income.

Is the cash balance enough to fund the development pipeline without raising capital?

The company holds substantial liquid assets relative to its burn rate and development commitments. At the current operating cash flow trajectory, the runway appears to extend many years without dilutive financing. However, if major partner programs fail or new acquisitions accelerate, capital needs could rise sharply. The company has historically been willing to acquire programs and clinical-stage assets, which can consume cash quickly.

What is the LGND stock price today?

The last price recorded for Ligand Pharmaceuticals Incorporated (LGND), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the LGND price target?

The analyst consensus price target for Ligand Pharmaceuticals Incorporated (LGND), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 44 figures on this page — 38 from Financial Modeling Prep (FMP), 2 with no recorded source, 2 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Quarterly income statement (USD thousands)
  • 1. What is Ligand Pharmaceuticals (LGND), and what does it report?: Revenue by segment; Quarterly income statement (USD thousands); Business description
  • 2. What do the latest results show for Ligand Pharmaceuticals (LGND)?: Quarterly income statement (USD thousands); Management outlook — dated call excerpts; Reported versus estimated, last 8 quarters
  • 3. What are the financial strengths and risks for Ligand Pharmaceuticals (LGND)?: Cash, investments and debt; Quarterly income statement (USD thousands); Trailing twelve-month ratio set
  • 4. What should you watch next at Ligand Pharmaceuticals (LGND)?: Management outlook — dated call excerpts; Next earnings report; Analyst revenue and earnings estimates (average)
  • 5. How does Ligand Pharmaceuticals compare with its peers?: Revenue by segment; Employees; Trailing twelve-month ratio set
  • FAQ: What is Captisol and why does Ligand sell it?: Business description; Revenue by segment
  • FAQ: Does Kyprolis generate most of Ligand's royalty income?: Revenue by segment; Business description
  • FAQ: Why did earnings swing so dramatically between quarters?: Quarterly income statement (USD thousands); Revenue by segment; Reported versus estimated, last 8 quarters
  • FAQ: Is the cash balance enough to fund the development pipeline without raising capital?: Cash, investments and debt; Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold LGND

Funds in our ETF coverage that list LGND among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
Validea Market Legends ETF (VALX)1.87%